• RESEARCH

    Compact plasma ctDNA panel detects oncogenic variants in 91% of evaluable newly diagnosed metastatic CRC patients

    A 10-gene hybrid-capture sequencing panel identified baseline oncogenic variants in 32 of 35 evaluable patients (91.4%) with newly diagnosed unresectable metastatic colorectal cancer, showing 84.2% sensitivity and 100% specificity compared with routine tissue PCR for shared RAS/BRAF targets. (Int J Mol Sci)